Brain radiation plus ivonescimab and chemo for lung cancer that spread to the brain
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether giving radiation therapy (called stereotactic radiotherapy) to the brain before or along with a combination of an experimental drug (ivonescimab) and chemotherapy can help treat non-small cell lung cancer that has spread to the brain. It compares this approach to just receiving the drug and chemotherapy without the brain radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other parts of the body, but does not have a specific genetic change that would allow you to take a targeted pill as your first treatment.
- You must have brain metastases (cancer spread to the brain) that are newly diagnosed and not yet treated (except possibly removed by surgery). You should have 1 to 10 brain spots, with at least one that is at least 5x5 mm in size. The largest spot must be less than 30 mm in diameter, and the total volume of all spots must be less than 30 mL.
- You can have mild symptoms from the brain metastases, as long as you are taking at most 4 mg of dexamethasone (a steroid) per day to control them. Seizures must be controlled.
- You must not have had radiation therapy to the brain before, and you must not have had chemotherapy or immunotherapy for cancer that has spread (unless it was as part of your initial treatment and finished at least 6 months before the spread was found).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.
This Phase 2 trial studies whether giving immunotherapy along with a precise form of brain radiation can control brain metastases from non-small cell lung cancer. It may help by shrinking or stabilizing spots in the brain while your body’s immune system is also activated.
This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.
This Phase 3 study tests whether immunotherapy or targeted medicine, with or without a one-time focused brain radiation procedure, can control brain metastases from melanoma or non-small cell lung cancer. It mainly enrolls people who have no (or minimal) brain symptoms and are newly diagnosed in the brain (except for certain recent brain surgery).
This trial tests a new immunotherapy drug called ivonescimab combined with focused radiation therapy (SBRT) for patients with early-stage non-small cell lung cancer who cannot or prefer not to have surgery. The goal is to see if this combination can effectively treat the cancer while being tolerable.
This trial tests a new way to deliver radiation to brain metastases from non-small cell lung cancer, using MRI scans to guide the treatment and reduce the area exposed. The goal is to see if this approach is safe and effective while possibly lowering side effects.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.